Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 3/20 | 0.41 |
| ▸ | DGAT1 | O75907 | 4/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | TOP2A | P11388 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CDC25A | P30304 | 1/20 | 0.38 |
| ▸ | CDC25B | P30305 | 1/20 | 0.38 |
| ▸ | PHGDH | O43175 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2981625 | 0.90 | HSD11B1 (0.40) | TP53DGAT1HDAC6HSD11B1MAPT | |
| SCHEMBL2982974 | 0.89 | SMN1; SMN2 (0.50) | TP53DGAT1MAPTSMN1; SMN2LMNA | |
| SCHEMBL2987136 | 0.86 | MEN1 (0.46) | TP53HSD11B1MAPTSMN1; SMN2LMNA | |
| SCHEMBL2997693 | 0.83 | GAA (0.46) | TP53DGAT1MAPTLMNAALDH1A1 | |
| SCHEMBL22530202 | 0.81 | HSD11B1 (0.49) | PIN1HSD11B1SMN1; SMN2CDC25ACDC25B | |
| SCHEMBL2984482 | 0.79 | KMT2A (0.43) | TP53DGAT1MAPTSMN1; SMN2LMNA | |
| SCHEMBL11525112 | 0.78 | NPC1 (0.54) | HDAC6HSD11B1MAPTLMNACDC25A | |
| SCHEMBL2991428 | 0.75 | HSD11B1 (0.39) | TP53HSD11B1MAPTRAB9AALDH1A1 | |
| SCHEMBL2990968 | 0.73 | HSD11B1 (0.58) | HSD11B1SMN1; SMN2LMNARAB9AALDH1A1 | |
| SCHEMBL2987116 | 0.70 | HSD11B1 (0.44) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776897-B2 | such as 3-[1-(5-chloro-2-thienyl)cyclopenty]-5,6,7,8,9,10-hexahydro [1,2,4]triazolo[4,3-a]azocine, having a strong 11 beta -hydroxysteroid dehydrogenase type 1inhibitory activity and exhibiting an excellent blood-glucose level-lowering action, used for the therapy of diabetes and insulin resistance | ASTELLAS PHARMA INC. (JP) | 2010-08-17 | — | — | US | disclosed |
| US-20070259854-A1 | Triazole Derivative or Salt Thereof | ASTELLAS PHARMA INC. (JP) | 2007-11-08 | — | — | US | disclosed |
| EP-1790641-A1 | TRIAZOLE DERIVATIVE OR SALT THEREOF | Astellas Pharma Inc. (JP) | 2007-05-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259854-A1 | Triazole Derivative or Salt Thereof | HSD11B1, HSD11B2, HSD3B1 | TP53 4289/4885DGAT1 295/4885HDAC6 540/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.